TY  - JOUR
AU  - Stević, Ivana
AU  - Petrović, Nemanja
AU  - Janković, Slobodan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5266
AB  - To satisfy the needs of pediatric and other patients with focal onset seizures who cannot swallow solid dosage forms of zonisamide, an oral liquid form of this drug is necessary in clinical practice. Although there are two oral suspensions of zonisamide with marketing authorization (MA), there are issues of availability and high cost which limit their use and inspire extemporaneous compounding. Extemporaneously compounded oral suspensions of zonisamide are prepared according to different formulas and vary in stability; therefore it is essential to test this characteristic. Bioequivalence of extemporaneously compounded oral suspensions has never been tested, and the efficacy and safety of zonisamide oral suspensions have generally not been demonstrated in clinical trials. As a narrow therapeutic window drug, zonisamide requires precision in dosing, which could be achieved only with dosage forms with established bioavailability, efficacy, and safety. In order to avoid underdosing and toxicity with zonisamide oral suspensions and utilize their full therapeutic potential, it is necessary to perform bioequivalence studies with each variation of extemporaneously compounded oral suspension and also clinical trials with both commercial and extemporaneous oral suspensions of zonisamide.
PB  - Dove Medical Press Ltd
T2  - Patient Preference and Adherence
T1  - Bioequivalence of Different Formulations of Zonisamide Oral Suspensions: A Short Review
VL  - 17
SP  - 2841
EP  - 2845
DO  - 10.2147/PPA.S383038
ER  - 

@article{
author = "Stević, Ivana and Petrović, Nemanja and Janković, Slobodan",
year = "2023",
abstract = "To satisfy the needs of pediatric and other patients with focal onset seizures who cannot swallow solid dosage forms of zonisamide, an oral liquid form of this drug is necessary in clinical practice. Although there are two oral suspensions of zonisamide with marketing authorization (MA), there are issues of availability and high cost which limit their use and inspire extemporaneous compounding. Extemporaneously compounded oral suspensions of zonisamide are prepared according to different formulas and vary in stability; therefore it is essential to test this characteristic. Bioequivalence of extemporaneously compounded oral suspensions has never been tested, and the efficacy and safety of zonisamide oral suspensions have generally not been demonstrated in clinical trials. As a narrow therapeutic window drug, zonisamide requires precision in dosing, which could be achieved only with dosage forms with established bioavailability, efficacy, and safety. In order to avoid underdosing and toxicity with zonisamide oral suspensions and utilize their full therapeutic potential, it is necessary to perform bioequivalence studies with each variation of extemporaneously compounded oral suspension and also clinical trials with both commercial and extemporaneous oral suspensions of zonisamide.",
publisher = "Dove Medical Press Ltd",
journal = "Patient Preference and Adherence",
title = "Bioequivalence of Different Formulations of Zonisamide Oral Suspensions: A Short Review",
volume = "17",
pages = "2841-2845",
doi = "10.2147/PPA.S383038"
}

Stević, I., Petrović, N.,& Janković, S.. (2023). Bioequivalence of Different Formulations of Zonisamide Oral Suspensions: A Short Review. in Patient Preference and Adherence
Dove Medical Press Ltd., 17, 2841-2845.
https://doi.org/10.2147/PPA.S383038

Stević I, Petrović N, Janković S. Bioequivalence of Different Formulations of Zonisamide Oral Suspensions: A Short Review. in Patient Preference and Adherence. 2023;17:2841-2845.
doi:10.2147/PPA.S383038 .

Stević, Ivana, Petrović, Nemanja, Janković, Slobodan, "Bioequivalence of Different Formulations of Zonisamide Oral Suspensions: A Short Review" in Patient Preference and Adherence, 17 (2023):2841-2845,
https://doi.org/10.2147/PPA.S383038 . .